American Journal of Hematology

Article	Citations
Clinical events in a long‐term prospective neonatal cohort of children with sickle cell disease: Evidence for a high disease burden without systematic preventive intensification with hydroxyurea	371
Clonal hematopoiesis in unexplained cytopenias	327
Deciphering clonal architecture and evolutionary dynamics of secondary acute myeloid leukemia and donor‐derived myelodysplastic syndrome using single‐cell multi‐omics analysis	228
	201
The latest insights into rare blood disorders: Diagnosis and treatment strategies	148
Comparative thrombotic risk associated with CALR1, CALR2, and JAK2 V617F mutations in essential thrombocythemia	141
Complete response to pembrolizumab and radiation in a patient with HIV‐negative, EBV‐positive plasmablastic lymphoma	137
Paroxysmal nocturnal hemoglobinuria and vascular liver disease: Eculizumab therapy decreases mortality and thrombotic complications	131
Identifying signs and symptoms of AL amyloidosis in electronic health records using natural language processing, diagnosis codes, and manually abstracted registry data	123
Issue Information	120
Allogeneic stem cell transplantation for children and adolescents/young adults with de novo blastic phase chronic myeloid leukemia in the tyrosine kinase inhibitor era	116
CD19‐negative relapse in adult patients with relapsed/refractory B‐cell precursor acute lymphoblastic leukemia following treatment with blinatumomab‐a post hoc analysis	113
Congenital X‐linked neutropenia with myelodysplasia and somatic tetraploidy due to a germline mutation in SEPT6	103
Treatment Effectiveness of Venetoclax‐Based Therapy After Bruton Tyrosine Kinase Inhibitors in Chronic Lymphocytic Leukemia: An International Real‐World Study	97
NOTCH1 Mutations Are Associated With Therapy‐Resistance in Patients With B‐Cell Lymphoma Treated With CD20xCD3 Bispecific Antibodies	93
Novel Flow Cytometric Antibody Panel and Dedicated Analysis Algorithm for Automated Fully Standardized Minimal Residual Disease Detection in Chronic Lymphocytic Leukemia	88
Black multiple myeloma patients undergoing upfront autologous stem cell transplant have similar survival outcomes compared to Whites: A propensity‐score matched analysis	85
Intravenous Iron Associated Hypophosphatemia: Much More Than a Laboratory Curiosity	81
Therapeutic Errors Associated With Antithrombotic Medications Reported to United States Poison Centers	81
Efficacy and safety of ferric carboxymaltose infusion in reducing anemia in patients receiving chemotherapy for nonmyeloid malignancies: A randomized, placebo‐controlled study (IRON	70
A population‐based study of outcomes in polycythemia vera, essential thrombocythemia, and primary myelofibrosis in the United States from 2001 to 2015: Comparison with data from a Mayo Clinic single i	69
Association of MPL K39N and R102P heterozygous germline mutations lead to hereditary thrombocytosis	62
NPM1‐mutated myeloid neoplasm with low percentage of blasts	61
Improving healthspan among people with sickle cell disease: Leveraging precision health in an era of treatments with curative intent	59
Unveiling the genetic landscape of suspected congenital dyserythropoietic anemia type I: A retrospective cohort study of 36 patients	56

Aspirin use in essential thrombocythemia: Once‐daily or twice‐daily or not at all?	55
Infections in patients with chronic lymphocytic leukemia treated with time limited targeted drug combinations	55
Long‐term effectiveness of eliglustat treatment: A real‐world analysis from the International Collaborative Gaucher Group Gaucher Registry	51
Increased blood reactive oxygen species and hepcidin in obstructive sleep apnea precludes expected erythrocytosis	50
A novel missense variant in ATP11C is associated with reduced red blood cell phosphatidylserine flippase activity and mild hereditary hemolytic anemia	49
Characteristics and prevalence of antibiotic allergies in patients with sickle cell disease: A single‐center retrospective study	48
Italian patients with hemoglobinopathies exhibit a 5‐fold increase in age‐standardized lethality due to SARS‐CoV‐2 infection	48
Sustained, complete response to pexidartinib in a patient with CSF1R‐mutated Erdheim–Chester disease	47
Complement‐targeted therapeutics: An emerging field enabled by academic drug discovery	46
Tocilizumab for severe acute chest syndrome in a child with sickle cell disease and dramatically high interleukin‐6 values in endotracheal and pleural fluids	46
Rainer Prohaska (1943–2022)	44
Clinical impact of cytomorphology in mast cell leukemia	43
Sickle cell allele HBB‐rs334(T) is associated with decreased risk of childhood Burkitt lymphoma in East Africa	42
Normal B cells express ZAP70 in chronic lymphocytic leukemia: A link between autoimmunity and lymphoproliferation?	42
Tandem autologous stem cell transplantation in patients with persistent bone marrow minimal residual disease after first transplantation in multiple myeloma	40
Natural killer cells: Innate immune system as a part of adaptive immunotherapy in hematological malignancies	40
Drug‐induced hypersensitivity syndrome and eosinophils in skin biopsy in a patient with pancytopenia	39
Bruton tyrosine kinase inhibitors in the management of Waldenström macroglobulinemia	38
Outcome after hematopoietic stem cell transplantation in patients with extranodal natural killer/T‐Cell lymphoma, nasal type: A French study from the Société Francophone de Greffe de Moelle	37
Immune cell kinetics and antibody response in COVID‐19 patients with low‐count monoclonal B‐cell lymphocytosis	37
Acute Epstein‐Barr virus associated haemophagocytosis in an Asian female: What is the diagnosis?	36
Granular Mott cells in multiple myeloma	36
Muscular de‐conditioning and reduced cardiac inotropism due to iron deposition reduce exercise tolerance in beta thalassemia major	34
The insertion site is the main risk factor for central venous catheter‐related complications in patients with hematologic malignancies	34
Occult recurrent breast cancer masquerading as thrombotic thrombocytopenic purpura	33
Diagnosis of histiocytic sarcoma by bone marrow aspiration	33
Relationship between comorbidities, mutational profile, and outcome after intensive chemotherapy in patients older than 60 years with acute myeloid leukemia: Assessment of different risk scores	33
The immune system in multiple myeloma and precursor states: Lessons and implications for immunotherapy and interception	33
Clinical, biological, and molecular genetic features of Richter syndrome and prognostic significance: A study of the French Innovative Leukemia Organization	33
Issue Information	33
Clonal hematopoiesis in patients with Covid‐19 is stable and not linked to an aggravated clinical course	32
Oligoclonal gamma‐delta T cell expansion in response to Ehrlichia infection	31
Breast implant‐associated anaplastic large cell lymphoma	31
	31
Multi‐organ dysfunction secondary to abrupt discontinuation of voxelotor in a patient with severe sickle cell disease	31
Acute thrombocytopenia suggesting thrombotic microangiopathy	30
A t(6;14;9)(p22;q22;q34) three‐way translocation: Description of a cytogenetically visible variant t(6;9) in acute myeloid leukemia	30
An unusual lymphoma involving the GI tract and bone marrow	30
Health‐related quality of life in transplant‐eligible patients with newly diagnosed multiple myeloma treated with daratumumab, lenalidomide, bortezomib, and dexamethasone: Patient‐reported outcomes fr	29
Clinically meaningful improvements in patient‐reported outcomes in mitapivat‐treated patients with pyruvate kinase deficiency	29
Pediatric refractory chronic immune thrombocytopenia: Identification, patients' characteristics, and outcome	29
Hemolysis after high‐dose intravenous immunoglobulin: An under‐appreciated sequelae	29
Exploring the landscape of somatic ASXL2 mutations in myeloid neoplasms: Frequency and clinical implications	29
Novel germline JAK2R715T mutation causing PV‐like erythrocytosis in 3 generations. Amelioration by Ropeg‐Interferon	29
Making a virtue out of an evil: Are red blood cells from chronic mountain sickness patients eligible for transfusions?	28
Intravenous ferric derisomaltose for the treatment of iron deficiency anemia	28
Issue Information	28
Issue Information	27
	27
Is ≥ 100% the magic number to rule out the laboratory diagnosis of von Willebrand disease based on initial testing?	27

Issue Information	27
Clinical characteristics of cytomegalovirus‐positive pediatric acute lymphoblastic leukemia at diagnosis	27
Pretreatment clinical and genetic factors predict early post‐treatment mortality in fit AML patients following induction	27
Innovative strategies to improve hematopoietic stem cell transplant outcomes in myelofibrosis	26
Single agent subcutaneous blinatumomab for advanced acute lymphoblastic leukemia	26
Megakaryocyte morphology with GATA2 germline mutation	25
Germline DDX41 mutant predisposition syndromes: Slow driver states to hematological malignancies	25
Hemolytic crisis due to Covid‐19 vaccination in a woman with cold agglutinin disease	25
Bendamustine lymphodepletion is a well‐tolerated alternative to fludarabine and cyclophosphamide lymphodepletion for axicabtagene ciloleucel therapy for aggressive B‐cell lymphoma	25
Teclistamab in patients with multiple myeloma and impaired renal function	25
Erythropoietin‐secreting metanephric adenoma presenting as erythrocytosis	25
Follicular lymphoma: 2023 update on diagnosis and management	25
Increased transferrin protects from thrombosis in Chuvash erythrocytosis	24
Mutation landscape of normal karyotype myelodysplastic syndromes and their prognostic impact	24
Real‐world treatment patterns and outcomes in a national study of veterans with Waldenström macroglobulinemia, 2006–2019	24
Hematopoietic stem cell transplantation from haploidentical offspring donors using post‐transplant cyclophosphamide versus human leukocyte antigen‐matched siblings in older patients with myelodysplast	24
Issue Information	24
Daratumumab monotherapy for relapsed POEMS syndrome	24
Bone marrow granulomatous reaction to silicone from breast implants	24
A rare case of catastrophic antiphospholipid syndrome triggered by estrogen‐containing oral contraceptives in a patient with double heterozygous factor V Leiden and prothrombin G20210A muta	24
	23
Risk of infection in MPN patients in the era of Covid‐19: A prospective multicenter study of 257 patients from the CML‐MPN Quebec Rese	23
Multiple myeloma with central nervous system relapse presenting as right pupil‐sparing complete third nerve palsy	23
Moving toward more molecular classifications of myelodysplastic syndrome and acute myeloid leukemia	23
Hematological support of patients with significant anemia who decline red blood cell blood transfusion	23
Health‐related quality of life in patients with relapsed/refractory multiple myeloma treated with pomalidomide and dexamethasone ± subcutaneous daratumumab: Patient‐reported outcomes from the APOLLO t	23
Issue Information	22
Comparable relapse incidence after unrelated allogeneic stem cell transplantation with post‐transplant cyclophosphamide versus conventional anti‐graft versus host disease prophylaxis in patients with	22
Imatinib versus newer generation TKIs for upfront therapy in chronic phase chronic myeloid leukemia: What is the rationale for paying more to get the same survival benefit?	22
Outcome prediction by the knowledge bank approach in acute myeloid leukemia patients undergoing allogeneic stem cell transplantation	22
Circulating rhabdoid tumor cells in the peripheral blood of a neonate	22
Multiple myeloma: 2024 update on diagnosis, risk‐stratification, and management	22
Issue Information	22
Accurate identification of a precursor B‐cell neoplasm	22
Self‐pay laboratory charges for iron deficiency diagnosis in the Boston and New Haven metropolitan areas	22
Progress in survival following three decades of allogeneic hematopoietic cell transplantation for myelodysplastic syndrome: A real‐world registry study in Japan	21
Is it time to reconsider molecular response milestones in chronic myeloid leukemia?	21
Unraveling the mystery of the spleen	21
Prediction of early (4‐week) mortality in acute myeloid leukemia with intensive chemotherapy	21
Secondary acquisition of the Philadelphia chromosome in acute lymphoblastic leukemia	21
Recent advances in the pathophysiology of PIEZO1‐related hereditary xerocytosis	21
Differentiation syndrome with lower‐intensity treatments for acute myeloid leukemia	21
Issue Information	21
Severe SARS‐CoV‐2 infection in rituximab‐treated patients with autoimmune cytopenia: A multicenter observational study	20
Cardiac effects 2 years after successful non‐myeloablative human leukocyte antigen‐matched related donor hematopoietic cell transplants in sickle cell disease	20
Blinatumomab is associated with favorable outcomes in patients with B‐cell lineage acute lymphoblastic leukemia and positive measurable residual disease at a threshold of 10−4 and higher	20
The evolving landscape of COVID‐19 and post‐COVID condition in patients with chronic lymphocytic leukemia: A study by ERIC, the European research initiative	20
	20
Clinical, genomic, and transcriptomic differences between myelodysplastic syndrome/myeloproliferative neoplasm with ring sideroblasts and thrombocytosis (MDS/MPN‐RS‐T) and myelodysplastic s	20
Impact of autologous hematopoietic cell transplantation on disease burden quantified by next‐generation sequencing in multiple myeloma treated with quadruplet therapy	20
Clinico‐genetic and prognostic analyses of 716 patients with primary myelodysplastic syndrome and myelodysplastic syndrome/acute myeloid leukemia based on the 2022 International	20
Effect of donor age in patients with acute myeloid leukemia undergoing haploidentical hematopoietic cell transplantation vary by conditioning intensity and recipient age	19
Monotypic plasmacytoid cells mimicking lymph node malignancy in the setting of COVID‐19 recovery	19
Comprehensive profiling of clinical JAK inhibitors in myeloproliferative neoplasms	19
Basiliximab for steroid‐refractory acute graft‐versus‐host disease: A real‐world analysis	19
Idarubicin plus BuCy versus BuCy conditioning regimens for intermediate‐risk acute myeloid leukemia in first complete remission undergoing auto‐HSCT: An open‐label, mu	19
A newly identified ferritin L‐subunit variant results in increased proteasomal subunit degradation, impaired complex assembly, and severe hypoferritinemia	19
Favorable outcome of non‐myeloablative allogeneic transplantation in adult patients with severe sickle cell disease: A single center experience of 200 patients	19
Pseudoreticulocytosis in a patient with myelodysplastic syndrome	19
The treatment of hairy cell leukemia with a focus on long lasting responses to cladribine: A 30‐year experience	19
Young platelet millionaires with essential thrombocythemia	19
The transcriptome‐wide landscape of molecular subtype‐specific mRNA expression profiles in acute myeloid leukemia	19
Artificial intelligence generated leukemia cell images	18
Long‐term risk of venous thromboembolism among patients with gastrointestinal non‐neoplastic and neoplastic diseases: A prospective cohort study of 484 211 individuals	18
Increased CD8 T‐cell immunity after COVID‐19 vaccination in lymphoid malignancy patients lacking adequate humoral response: An immune compensation mechanism?	18
Assessing hypercoagulability and VTE risk using thromboelastography and Khorana score in women with cancers receiving chemotherapy	18
Ruxolitinib for refractory large granular lymphocyte leukemia	18
BNT162b2 mRNA SARS‐CoV‐2 vaccination does not cause upregulation of endothelial activation markers or hypercoagulability: A prospective, single‐arm, longitudinal study	18
SARS‐CoV‐2 infection in patients with β‐thalassemia: Experience from Lebanon	18
Burden of disease, treatment utilization, and the impact on education and employment in patients with sickle cell disease: A comparative analysis of high‐ and low‐ to middle‐income countries for the i	17
Real‐world experience with venetoclax and hypomethylating agents in myelodysplastic syndromes with excess blasts	17
Loss of alpha globin genes is associated with improved microvascular function in patients with sickle cell anemia	17
Dismal outcomes of patients with relapsed/refractory Philadelphia chromosome‐negative B‐cell acute lymphoblastic leukemia after failure of both inotuzumab ozogamicin and blinatumomab	17
The outcomes of patients with chronic myeloid leukemia treated with third‐line BCR::ABL1 tyrosine kinase inhibitors	17
Single‐agent daratumumab for refractory POEMS syndrome	17
Impact of sex on outcomes in patients with hairy cell leukemia. An HCL patient data registry analysis	17
Approach to a patient with “double refractory” chronic lymphocytic leukemia: “Double, double toil and trouble” (Shakespeare)	17
Extranodal natural killer/T‐cell lymphoma nasal type in a western population: Molecular profiling identifies new therapeutic targets	17
Isatuximab plus carfilzomib and dexamethasone in patients with relapsed multiple myeloma based on prior lines of treatment and refractory status: IKEMA subgroup analysis	17
Hairy cell leukemia 2024: Update on diagnosis, risk‐stratification, and treatment—Annual updates in hematological malignancies	17

Transcranial doppler velocity in iron‐deficient Nigerian children with sickle cell anemia	16
Risk Factors and Prognostic Markers for Posterior Reversible Encephalopathy Syndrome in Patients With Thalassemia Major After Allogeneic Hematopoietic Stem Cell Transplantation	16
Age defining immune effector cell associated neurotoxicity syndromes in aggressive large B cell lymphoma patients treated with axicabtagene ciloleucel	16
De novo accelerated phase of chronic myeloid leukemia should be recognized even in the era of tyrosine kinase inhibitors	16
A framework for the clinical implementation of optical genome mapping in hematologic malignancies	16
A novel adoptive synthetic TCR and antigen receptor (STAR) T‐Cell therapy for B‐Cell acute lymphoblastic leukemia	16
Blastic Plasmocytoid Dendritic Cell Neoplasm With Pseudo‐Lymphoid Morphology Mimicking Lymphoid Malignancy	16
	16
Unselected donor‐derived hematopoietic stem cells boost for Chimeric Antigen Receptor T‐cell associated hematotoxicity	16
Patient characteristics that predict Richter's transformation in patients with chronic lymphocytic leukemia treated with ibrutinib	16
Eltrombopag improves platelet engraftment after haploidentical bone marrow transplantation: Results of a Phase II study	16
Clinical and molecular predictors of fibrotic progression in essential thrombocythemia: A multicenter study involving 1607 patients	15
Crushed deferasirox film‐coated tablets in pediatric patients with transfusional hemosiderosis: Results from a single‐arm, interventional phase 4 study (MIMAS)	15
Kinetics of anti‐SARS‐CoV‐2 neutralizing antibodies development after BNT162b2 vaccination in patients with amyloidosis and the impact of therapy	15
Clinical significance of clonal hematopoiesis in the setting of autologous stem cell transplantation for lymphoma	15
Epidemiology of clinically significant forms of alpha‐ and beta‐thalassemia: A global map of evidence and gaps	15
An integrated therapeutic approach to sickle cell disease management beyond infancy	15
Assessment of the 4‐factor score: Retrospective analysis of 586 CLL patients receiving ibrutinib. A campus CLL study	15
Serum erythropoietin levels in 696 patients investigated for erythrocytosis with JAK2 mutation analysis	15
Peripheral blood cells vacuoles in VEXAS syndrome	15
Patients with treated indolent lymphomas immunized with BNT162b2 have reduced anti‐spike neutralizing IgG to SARS‐CoV‐2 variants, but preserved antigen‐specific T cell	15
Thrombopoietin mimetic‐induced bone marrow fibrosis	15
Continuous treatment with Ibrutinib in 100 untreated patients with TP53 disrupted chronic lymphocytic leukemia: A real‐life campus CLL study	14
Clinical characteristics and overall survival among acute myeloid leukemia patients with TP53 gene mutation or chromosome 17p deletion	14
Validated international definition of the thrombocytopenia, anasarca, fever, reticulin fibrosis, renal insufficiency, and organomegaly clinical subtype (TAFRO) of idiopathic multicentric Castlema	14
The prognostic significance of macrocytosis in patients with myelodysplastic neoplasms	14
Humanized CD19‐targeted chimeric antigen receptor T (CAR‐T) cells for relapsed/refractory pediatric acute lymphoblastic leukemia	14
Clinical outcomes and microenvironment profiling in relapsed/refractory multiple myeloma patients with extramedullary disease receiving anti‐BCMA CAR T‐cell‐based therapy	14
Antibody response to COVID‐19 mRNA vaccine (Comirnaty) in myeloma patients treated with high‐dose melphalan and/or immunotherapy	14
Adverse events reported to the U.S. Food and Drug Administration Adverse Event Reporting System for tisagenlecleucel	14
Older patients with primary central nervous system lymphoma: Survival and prognostication across 20 U.S. cancer centers	14
Patient‐reported neurocognitive symptoms influence instrumental activities of daily living in sickle cell disease	14
Long‐term outcomes and predictors of early response, late relapse, and survival for patients treated with bispecific LV20.19 CAR T‐cells	14
Trial designs and endpoints for immune therapies in multiple myeloma	14
Parsaclisib for the treatment of primary autoimmune hemolytic anemia: Results from a phase 2, open‐label study	14
Romidepsin and lenalidomide‐based regimens have efficacy in relapsed/refractory lymphoma: Combined analysis of two phase I studies with expansion cohorts	14
Retrospective comparison of survival and responses to Fludarabine, Cytarabine, GCSF (FLAG) in combination with gemtuzumab ozogamicin (GO) or Idarubicin (IDA	14
Fetal hemoglobin per erythrocyte (HbF/F‐cell) after gene therapy for sickle cell anemia	14
Cost‐effectiveness of prophylactic emicizumab versus prophylactic recombinant factor VIII in patients with moderate or mild hemophilia A without inhibitors in the United States	14
2021 update on clinical trials in β‐thalassemia	14
Imatinib remains the best frontline therapy in patients with chronic myeloid leukemia: Critical analysis of the ASC4FIRST trial	14
Cerebral venous thrombosis post BNT162b2 mRNA SARS‐CoV‐2 vaccination: A black swan event	14
Hydroxyurea to prevent brain injury in children with sickle cell disease (HU Prevent)—A randomized, placebo‐controlled phase II feasibility/pilot study	13
Age barriers in allogeneic hematopoietic cell transplantation: Raising the silver curtain	13
The invisible lifeline: Intricacies of the global plasma supply	13
Are veterans at increased risk of myeloproliferative neoplasms?	13
COVID‐19 mRNA vaccine‐associated cerebral venous thrombosis: Rare adverse event or coincidence?	13
A common pattern of somatic mutations in t‐MDS/AML of patients treated with PARP inhibitors for metastatic ovarian cancer	13
At what COST?: A prospective longitudinal cohort assessment of financial toxicity, quality of life, and associated risk factors in patients with plasma cell disorders	13
Alemtuzumab in relapsed immune severe aplastic anemia: Long‐term results of a phase II study	13
Pituitary apoplexy in acute promyelocytic leukemia	13
A phase 1b study of venetoclax and azacitidine combination in patients with relapsed or refractory myelodysplastic syndromes	13
NPM1‐mutated acute myeloid leukemia: New pathogenetic and therapeutic insights and open questions	13
Issue Information	13
The cognitive age in medicine: Artificial intelligence, large language models, and iterative intelligence	13
Impact of induction regimens intensity and allogeneic stem cell transplantation on survival of patients with Philadelphia chromosome‐positive acute lymphoblastic leukemia: A multi‐institutional study	13
A phase 1 clinical trial of oral eltanexor in patients with relapsed or refractory multiple myeloma	13
TLR8/TLR7 dysregulation due to a novel TLR8 mutation causes severe autoimmune hemolytic anemia and autoinflammation in identical twins	13
R‐miniCHOP versus R‐CHOP in elderly patients with diffuse large B‐cell lymphoma: A propensity matched population‐based study	13
A matching‐adjusted indirect comparison of acalabrutinib versus zanubrutinib in relapsed or refractory chronic lymphocytic leukemia	13
Overall Survival in Male Patients With Advanced Hematological Disease (Mostly Acute Leukemia) Is Influenced by CYP1B1 C432G Polymorphism and Donor Sex in Allogeneic Stem Cell Transpl	12
Cutaneous T‐cell lymphomas: 2023 update on diagnosis, risk‐stratification, and management	12
Real‐world Big‐data: Strengths and weaknesses of ASCO's CancerLinQ® discovery multiple myeloma dataset	12
Dendritic cell vaccines extend CAR T‐cell persistence and improve the efficacy of CD19 CAR T‐cell therapy in refractory or relapsed adult B‐ALL patients	12
Hyper‐CVAD and Sequential Blinatumomab Without and With Inotuzumab in Young Adults With Newly Diagnosed Philadelphia Chromosome‐Negative B‐Cell Acute Lymphoblastic Leukemia	12
Iron Deficiency in Familial Mediterranean Fever: A Study on 211 Adult Patients From the JIR Cohort	12
Mayo Genetic Risk Models for Newly Diagnosed Acute Myeloid Leukemia Treated With Venetoclax + Hypomethylating Agent	12
Low‐dose dasatinib 50 mg/day versus standard‐dose dasatinib 100 mg/day as frontline therapy in chronic myeloid leukemia in chronic phase: A propensity score analysis	12
Dosage of high‐dose methotrexate as CNS prophylaxis in DLBCL: A detailed analysis of toxicity and impact on CNS relapse	12
Molecular and clinicopathologic characterization of pediatric histiocytoses	12
Essential thrombocythemia: 2024 update on diagnosis, risk stratification, and management	12
Evaluating Minimal Residual Disease Negativity as a Surrogate Endpoint for Treatment Efficacy in Multiple Myeloma: A Meta‐Analysis of Randomized Controlled Trials	12
Blood Plasma Methylated DNA Markers in the Detection of Lymphoma: Discovery, Validation, and Clinical Pilot	12
Roxadustat for the treatment of anemia in patients with lower‐risk myelodysplastic syndrome: Open‐label, dose‐selection, lead‐in stage of a phase 3 study	12
Evaluation of the clinical significance of global mRNA alternative splicing in patients with acute myeloid leukemia	12
Clinical implications of SRSF2 mutations in AML patients undergoing allogeneic stem cell transplantation	12
Comparison of the International Consensus and 5th WHO edition classifications of adult myelodysplastic syndromes and acute myeloid leukemia	12
Intranasal fentanyl works—Why are we not using it more to treat acute pain in sickle cell disease?	12
Oh node: Extranodal nodular involvement of chronic lymphocytic leukemia in the colon	12
Breaking the Bone Marrow Barrier: Peripheral Blood as a Gateway to Measurable Residual Disease Detection in Acute Myelogenous Leukemia	12
Adoptive transfer of functional SARS‐COV‐2‐specific immunity from donor graft to hematopoietic stem cell transplant recipients	11
Primary Effusion Lymphoma Prognostic Score (PEL‐PS): A Validated International Prognostic Score in HIV‐Associated Primary Effusion Lymphoma	11
Biologic features and clinical outcomes in newly diagnosed myelodysplastic syndrome with KMT2A rearrangements	11
Optimizing the diagnostic workflow for acute lymphoblastic leukemia by optical genome mapping	11
Hereditary stomatocytosis in the general population: A genetically based prevalence estimate from a 109 039 individual Danish cohort	11
Sequence analyses of relapsed or refractory diffuse large B‐cell lymphomas unravel three genetic subgroups of patients and the GNA13 mutant as poor prognostic biomarker, results of <	11
Aggressive T‐cell lymphomas: 2021 Updates on diagnosis, risk stratification and management	11
CORRIGENDUM	11
Relative prognostic value of flow cytometric measurable residual disease before allogeneic hematopoietic cell transplantation for adults with MDS/AML or AML	11
Natural history, predictors of development of extramedullary disease, and treatment outcomes for patients with extramedullary multiple myeloma	11
Influence of racial and ethnic identity on overall survival in patients with chronic lymphocytic leukemia	11
Thrombosis in multiple myeloma: Risk estimation by induction regimen and association with overall survival	11
CORRIGENDUM	11
Prognostic significance of early acute splenic sequestration in children with severe sickle cell genotypes: A comprehensive longitudinal neonatal cohort study	11
Efficacy and safety of zanubrutinib monotherapy for chronic lymphocytic leukemia/small lymphocytic lymphoma: A multicenter, real‐world study in China	11